The Russian pharmaceutical company NovaMedica has announced the production and market launch of the first large batch of the drug Relonova® intended for relief of migraine-associated headaches.
In January–May 2023, Russian manufacturers produced 282 billion rubles’ of pharmaceutical drugs (manufacturer’s prices, VAT included), down 5.8% from the same period in 2022.
In January–March 2023, the online sales or reservations of pharmacy products (pharmaceutical drugs and parapharmaceuticals) in Russia were 80.2 billion rubles (end-user prices, VAT included), up 2.3% from January–March 2022 (against 69.6% in Q1 2022, with its rush demand).
On June 16, GEROPHARM and the Government of Saint Petersburg at SPIEF-2023 signed a cooperation agreement to implement the investment project aimed at expanding the manufacture of medicinal products and increasing their export potential.
Market participants were significantly less active in early 2023 than during the rush demand in the spring of 2022. However, both inflation rates and stable household incomes now allow us to make optimistic industry growth forecasts, at least in the short term.